Evidence map›Paper›PMID 31165208›Full record

ReviewDer Nervenarzt2019

[Antisense therapies for neurological diseases].

Stefan-M Pulst

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Der Nervenarzt, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Stefan-M PulstDepartment of Neurology, University of Utah, CNC Building, 5th Floor, 175 N Medical Drive E, 84132, Salt Lake City, UT, USA. stefan.pulst@hsc.utah.edu.
University of Utah · US

Funding

Spinocerebellar Ataxia Type 2 Gene and Gene ProductR37NS033123 · NINDS · UNIVERSITY OF UTAH · PI PULST, STEFAN M. · 2014 to 2020
$3.6M
RNA Granules in Cerebellar NeurodegenerationR01NS097903 · NINDS · UNIVERSITY OF UTAH · PI SCOLES, DANIEL R · 2017 to 2021
$2.7M
Antisense Oligonucleotides for treating Spinocerebellar Ataxia Type 2U01NS103883 · NINDS · UNIVERSITY OF UTAH · PI PULST, STEFAN M., SCOLES, DANIEL R · 2018 to 2020
$1.9M
Antisense oligonucleotides for the treatment of spinocerebellar ataxia type 2R21NS081182 · NINDS · UNIVERSITY OF UTAH · PI PULST, STEFAN M., SCOLES, DANIEL R · 2013 to 2014
$408k
NINDS NIH HHS R01 NS097903NINDS NIH HHS R21 NS081182NINDS NIH HHS R37 NS033123NINDS NIH HHS U01 NS103883
6 · The paper itself

Abstract

Despite identification of many genes causing neurodegenerative diseases in the last decades, development of disease-modifying treatments has been slow. Antisense oligonucleotide (ASO) therapeutics for spinal muscular atrophy, Duchenne muscular dystrophy and transthyretin amyloidosis predict a robust future for ASOs in medicine. Perhaps the most significant advantage of ASO therapeutics over other small molecule approaches is that acquisition of the target sequence provides immediate knowledge of possible complementary oligonucleotide therapeutics. This review article describes the various types of ASOs, their therapeutic use and the current preclinical efforts to develop new ASO treatments.

Indexed as

Neurodegenerative DiseasesOligonucleotides, AntisenseGenetic TherapyHumansMuscular Atrophy, SpinalMuscular Dystrophy, DuchenneOligonucleotides, AntisenseAlzheimer diseaseAmyotrophic lateral sclerosisAntisense oligonucleotideATXN2Spinocerebellar ataxia

Identifiers

PMID31165208
PMCPMC6730669
OpenAlexW2948744391

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.